Almorexant

SKU: orb1305266

Description

Almorexant (ACT 078573) is a potent dual antagonist of orexin receptors OX1 (Ki=1.3 nM) and OX2 (Ki=0.17 nM). It is a valuable research tool for investigating sleep-wake regulation and has been utilized in both in vitro binding assays and in vivo models of insomnia.

Research Area

Cell Biology, Metabolism Research, Neuroscience, Pharmacology & Drug Discovery, Protein Biochemistry

Key Properties

• CAS Number: 871224-64-5
• MW: 512.56
• Purity: 98.02% (May vary between batches)
• Formula: C₂₉H₃₁F₃N₂O₃
• SMILES: C(CC1=CC=C(C(F)(F)F)C=C1)[C@H]2C=3C(=CC(OC)=C(OC)C3)CCN2[C@@H](C(NC)=O)C4=CC=CC=C4
• Target: Caspase,Calcium Channel,OX Receptor,Apoptosis
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.9 mM);DMSO:45 mg/mL (87.79 mM)

Bioactivity

• Target IC50:
  OX1:1.3 nM(ki)|OX2:0.17 nM(ki)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

OXReceptor, Cataplexy, Caspase, ACT078573, ACT-078573, ACT 078573, Almorexant, Ca channels, Ca2+ channels, Calcium Channel, Apoptosis, AsPC-1 cells, GPCR, hypocretin, Hypocretin Receptor, HCRT Receptor, HPAF-II cells, Inhibitor, inhibit, orexin, Orexin Receptor (OX Receptor), OX2, OX Receptor, OX1, narcolepsy, pancreatic cancer, Pancreatic ductal adenocarcinoma, PDAC

Compound Identifiers

PubChem CID

23727689